SCHEMBL1704512

SCHEMBL1704512

O=C(OCc1ccccc1)N1CCN(Cc2ccc(Br)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
LMNA P02545 2/20 0.66
HPGD P15428 2/20 0.66
HTT P42858 1/20 0.66
NPSR1 Q6W5P4 2/20 0.60
FAAH O00519 1/20 0.60
DUSP3 P51452 1/20 0.59
PTPN5 P54829 1/20 0.59
PTPN11 Q06124 1/20 0.59
GPR183 P32249 2/20 0.57
CYP2C19 P33261 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPT P10636 1/20 0.56
MAPK1 P28482 1/20 0.56
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
RAB9A P51151 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29943050 0.87 KDM4E (0.65) ALDH1A1LMNAHPGDHTTNPSR1
SCHEMBL23301159 0.87 KDM4E (0.65) ALDH1A1LMNAHPGDHTTNPSR1
SCHEMBL20353635 0.87 FAAH (0.60) NPSR1FAAHKMT2AMEN1
SCHEMBL4192541 0.87 KMT2A (0.56) ALDH1A1LMNAHPGDHTTNPSR1
SCHEMBL24200046 0.86 NPSR1 (0.58) ALDH1A1LMNANPSR1CYP2C19KMT2A
SCHEMBL29132085 0.86 SIGMAR1 (0.59) ALDH1A1LMNAHPGDHTTNPSR1
SCHEMBL4595454 0.85 KMT2A (0.57) ALDH1A1LMNANPSR1FAAHCYP2C19
SCHEMBL24199876 0.85 SIGMAR1 (0.68) ALDH1A1LMNAHTTFAAHCYP2D6
SCHEMBL13150170 0.84 KDM4E (0.60) ALDH1A1LMNANPSR1CYP2C19CYP3A4
SCHEMBL12018089 0.84 KMT2A (0.56) ALDH1A1LMNANPSR1CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US disclosed
US-8536182-B2 Benzylpiperazine derivatives and their medical use GLAXO GROUP LIMITED (GB) 2013-09-17 US disclosed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP disclosed
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2009-02-26 US disclosed
EP-1907374-A2 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-09 EP disclosed
WO-2007012479-A2 BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GPR68, GPR88, GPR55 ALDH1A1 1817/4885LMNA 3934/4885HPGD 787/4885
US-20130317041-A1 COMPOUNDS GPR68, GPR88, GPR35 ALDH1A1 1802/4885LMNA 3133/4885HPGD 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.